Status:
COMPLETED
Safety and Immunogenicity Study of a Ross River Virus (RRV) Vaccine
Lead Sponsor:
Alachua Government Services, Inc.
Conditions:
Ross River Virus Disease (RRVD)
Eligibility:
All Genders
18-40 years
Phase:
PHASE1
PHASE2
Brief Summary
The primary objective of this study is to assess the safety and tolerability of the Ross River Virus (RRV) Vaccine in a healthy young adult population. Other objectives of this study are to assess the...
Eligibility Criteria
Inclusion
- Are 18 to 40 years of age, inclusive, on the day of screening;
- Have an understanding of the study and its procedures, agree to its provisions, and give written informed consent prior to study entry;
- Are generally healthy;
- Are physically and mentally capable of participating in the study and following study procedures;
- Agree to keep a daily record of symptoms for the duration of the study;
- If female of childbearing potential - have a negative urine pregnancy test result within 24 hours of the scheduled first vaccination and agree to employ adequate birth control measures for the duration of the study.
Exclusion
- Have a history of RRV exposure or a history of travel to a RRV endemic area: Australia, West Papua, Papua New Guinea, Solomon Islands, New Caledonia, Fiji Islands, Samoa Islands and Cook Island;
- Have a Body Mass Index \> 35;
- Have an elevated blood pressure at screening of \> 159 mmHg systolic and/or \> 99 mmHg diastolic while seated and at rest and confirmed by two additional measurements taken at least 30 minutes apart (while seated and at rest);
- Have clinically significant abnormal clinical laboratory values at screening;
- Have clinically significant electrocardiographic abnormalities at screening;
- Test positive for Human Immunodeficiency Virus (HIV), Hepatitis B Surface Antigen (HbsAg) or Hepatitis C Virus (HCV);
- Have a history of cardiovascular disease;
- Have a history of immunodeficiency or autoimmune diseases;
- Have a history of arthritis (joint swelling, tenderness, warmth or erythema) on more than one occasion, not related to trauma (including running) or any episode of non-trauma related arthritis within the previous 6 months;
- Have an active neoplastic disease or have a history of hematological malignancy;
- Have a disease or are undergoing a form of treatment that can be expected to influence immune response. Such treatment includes, but is not limited to, systemic or high dose inhaled (\> 800 mg/day of beclomethasone dipropionate or equivalent), corticosteroids, radiation treatment or other immunosuppressive or cytotoxic drugs;
- Have a history of inflammatory or degenerative neurological disease (eg Guillain Barré, multiple sclerosis);
- Have received any vaccination within 2 weeks prior to vaccination in this study;
- Have received a blood transfusion or immunoglobulins within 30 days prior to vaccination in this study;
- Have donated blood or plasma within 30 days prior to vaccination in this study;
- Have a history of any vaccine related contraindicating event (eg, anaphylaxis, allergy to components of the test vaccine, other known contraindications);
- Have a rash, dermatologic condition or tattoos which may interfere with injection site reaction rating;
- Have a positive urine drug screen, (unless the detected drug is currently prescribed by a licensed health care provider and the continued administration of the drug would not otherwise exclude the subject from participation);
- Were administered an investigational drug within 6 weeks prior to study entry;
- Are concurrently participating in a clinical study that includes the administration of an investigational product;
- Are a member of the team conducting this study;
- Are in a dependent relationship with one of the study team members. Dependent relationships include close relatives (ie, children, partner/spouse, siblings, parents) as well as employees of the investigator or site personnel conducting the study;
- If female, are pregnant or lactating.
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2009
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT00717834
Start Date
June 1 2008
End Date
October 1 2009
Last Update
October 9 2015
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Privatklinik Leech
Graz, Austria, 8010
2
General Hospital Vienna, Department for Clinical Pharmacology
Vienna, Austria, 1090
3
Universiteit Antwerpen VAXINFECTIO
Antwerp, Belgium, 2610
4
Unité d´Investigation Clinique BioVallée
La Louvière, Belgium, 7100